Preclinical study points to a promising combined strategy for slowing the progression of t
An international research group led by researchers from VUB-UZ Brussels and KU Leuven has demonstrated that a combined approach targeting both the immune system and insulin-producing beta cells can slow the progression of type 1 diabetes more effectively than individual treatment
